Bicara Therapeutics Inc. (NASDAQ:BCAX) Shares Purchased by Bank of America Corp DE

Bank of America Corp DE lifted its position in shares of Bicara Therapeutics Inc. (NASDAQ:BCAX - Free Report) by 278.4% during the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 33,677 shares of the company's stock after purchasing an additional 24,777 shares during the quarter. Bank of America Corp DE owned about 0.06% of Bicara Therapeutics worth $587,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds also recently made changes to their positions in BCAX. BNP Paribas Financial Markets bought a new stake in Bicara Therapeutics in the fourth quarter worth $32,000. Legal & General Group Plc purchased a new stake in Bicara Therapeutics during the fourth quarter valued at $33,000. Summit Investment Advisors Inc. purchased a new stake in Bicara Therapeutics during the fourth quarter valued at $35,000. Virtus ETF Advisers LLC bought a new stake in Bicara Therapeutics during the fourth quarter valued at about $69,000. Finally, The Manufacturers Life Insurance Company grew its holdings in Bicara Therapeutics by 27.5% during the fourth quarter. The Manufacturers Life Insurance Company now owns 29,138 shares of the company's stock valued at $508,000 after purchasing an additional 6,279 shares during the period.

Wall Street Analyst Weigh In

BCAX has been the subject of several recent research reports. Cantor Fitzgerald reissued an "overweight" rating and set a $13.01 price target on shares of Bicara Therapeutics in a report on Thursday, March 13th. Wall Street Zen lowered Bicara Therapeutics from a "hold" rating to a "sell" rating in a research note on Thursday, May 22nd. Wells Fargo & Company raised Bicara Therapeutics from an "underweight" rating to an "equal weight" rating and set a $8.00 price objective for the company in a research note on Friday, May 23rd. HC Wainwright reduced their price target on Bicara Therapeutics from $44.00 to $41.00 and set a "buy" rating on the stock in a report on Friday, May 16th. Finally, Wedbush reiterated an "outperform" rating and issued a $30.00 price target on shares of Bicara Therapeutics in a report on Friday, May 23rd. One investment analyst has rated the stock with a sell rating, one has given a hold rating, seven have issued a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and an average target price of $31.86.

Bicara Therapeutics Trading Down 2.6%

BCAX traded down $0.31 during trading on Thursday, hitting $11.57. 472,922 shares of the stock were exchanged, compared to its average volume of 584,125. The firm has a 50 day simple moving average of $12.37 and a 200 day simple moving average of $13.97. Bicara Therapeutics Inc. has a 1 year low of $7.80 and a 1 year high of $28.09.

Bicara Therapeutics (NASDAQ:BCAX - Get Free Report) last announced its quarterly earnings results on Tuesday, May 13th. The company reported ($0.68) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.40) by ($0.28). Analysts forecast that Bicara Therapeutics Inc. will post -2.59 earnings per share for the current year.

About Bicara Therapeutics

Bicara Therapeutics Inc, a clinical-stage biopharmaceutical company, develops bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b) for the treatment of solid tumors.